Sign in
Taking people in United StatesNo phase

Blood Markers in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy

Studies blood samples from people with spreading leiomyosarcoma who are receiving chemotherapy.

Key facts

Who runs it
University of Michigan Rogel Cancer Center
Where
Ann Arbor, Boston, Columbus, Houston, Miami, Nashville, New York, Rochester, and Santa Monica, United StatesSee the 9 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Metastatic Leiomyosarcoma Biomarker Protocol
Status
Recruiting
People taking part
200 people, planned
Started
22 Dec 2022
Expected to end
Dec 2026
Type of study
Observational
Treatments tested
  • Plasma Collection
Record updated
24 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with leiomyosarcoma that cannot be removed by surgery or has spread. They must be starting first-line chemotherapy. Blood and tumor samples are studied as markers of how well treatment works.

Age
No age requirement.
Sex
All sexes can join.
Disease stage
Leiomyosarcoma that cannot be removed by surgery (unresectable) or has spread (metastatic), with target lesions per RECIST 1.1.
Earlier treatment
Receiving first-line chemotherapy with doxorubicin-based treatment or gemcitabine/docetaxel.
Biomarker or test result
No specific biomarker is required. Archival tumor tissue (slides or a tissue block, or a fresh frozen sample) is optional for the research.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement
  • Receiving first-line chemotherapy with doxorubicin- based or gemcitabine/docetaxel
  • Target lesions per RECIST 1.1
  • Optional archival tumor tissue including 1 H\&E-stained slide and unstained tumor tissue [either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample] available for study research

Where in United States

Also in 1 other country, 2 sites

  • University of Michigan Cancer CenterAnn Arbor, United StatesContact: Scott Schuetze, M.D., PhD.Taking people
  • Dana FarberBoston, United StatesContact: David Shulman, MDTaking people
  • Ohio State UniversityColumbus, United StatesContact: Gabriel Tinoco, MDTaking people
  • MD AndersonHouston, United StatesContact: Elise Nassif Haddad, MD, PhDTaking people
  • University of MiamiMiami, United StatesContact: Gina D'Amato, MDTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Elizabeth J Davis, MDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Sujana Movva, MDTaking people
  • Mayo ClinicRochester, United StatesContact: Brittany Siontis, MDTaking people
  • Sarcoma Oncology Research CenterSanta Monica, United StatesContact: Allyssa LingadTaking people

About the trial

What the trial wants to find out

Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.

The group in the trial

  • Enrolled Subjects

    Once enrolled subjects will provide Optional Archival Tissue, Optional Fresh tumor for a biopsy and blood collections at baseline, optional day 8 of cycle 1, day 1 of cycles 2-6 and at progression

    Treatment: Plasma Collection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy
Plain-language title
Blood Markers in Patients With Metastatic Leiomyosarcoma Receiving ChemotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
24 June 2026